AstraZeneca was domestically approved for the atomized-type product of its asthma treatment ‘Symbicort’
The new formulation of the AstraZeneca’s asthma treatment, Symbicort, is about to be launched. Its strength is the easier inhalation with the atomized type than the existing products.
According to the Ministry of Food and Drug Safety on the 31st, AstraZeneca has acquired approvals for the domest...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
